^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TT11

    i
    Other names: TT11, CD30.CAR-T cell therapy, TT11 CD30 CAR Ts, CD30.CAR-T, ATLCAR.CD30 cell therapy, ATLCAR.CD30 cells, CAR.CD30 T cell therapy, TT-11, TT 11
    Company:
    Baylor Scott & White Research Institute, Tessa Therap, UNC Lineberger Comprehensive Cancer Center
    Drug class:
    CD30-targeted CAR-T immunotherapy
    Related drugs:
    3d
    Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Aug 2038 --> Nov 2039 | Trial primary completion date: Sep 2027 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    TT11
    13d
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=18 --> 2 | Trial completion date: Aug 2030 --> Dec 2030 | Trial primary completion date: Sep 2026 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    2ms
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment open • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    4ms
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Aug 2030 | Trial primary completion date: Dec 2026 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    1year
    Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
    P1/2, N=40, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2040 --> Aug 2038 | Trial primary completion date: Aug 2025 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    TT11
    over1year
    ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (clinicaltrials.gov)
    P1/2, N=31, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    TT11 • ATLCAR.CD30.CCR4 cells
    almost2years
    CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (clinicaltrials.gov)
    P2, N=20, Recruiting, UNC Lineberger Comprehensive Cancer Center
    Trial completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    cyclophosphamide • fludarabine IV • TT11
    almost2years
    Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression • ALK negative • TNFRSF8 negative
    |
    TT11
    over2years
    Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
    P1/2, N=40, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2038 --> Aug 2040 | Trial primary completion date: Aug 2023 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    TT11
    over2years
    Combined autologous CD30.CAR-T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study) (ICML 2023)
    Two patients had cytokine release syndrome (Grade 1), which resolved without use of steroid or tocilizumab. Preliminary data demonstrated favorable safety profile and promising anti-tumor responses of CD30.CAR-T combined with nivo in r/r cHL patients after failure of frontline therapy. Evaluation of 15 patients enrolled is ongoing, and the clinical and ctDNA-MRD data will be presented at the meeting.
    Clinical • CAR T-Cell Therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression • PD-L2 overexpression
    |
    Opdivo (nivolumab) • Actemra IV (tocilizumab) • TT11
    over2years
    CERTAIN: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, Tessa Therapeutics | Trial primary completion date: Mar 2023 --> Nov 2022
    Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    TT11
    over2years
    ACTION: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (clinicaltrials.gov)
    P1b, N=15, Active, not recruiting, Tessa Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Checkpoint inhibition
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Opdivo (nivolumab) • fludarabine IV • TT11